Literature DB >> 25662675

The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin.

Zahra Kashi1, Parisa Masoumi2, Abdolkarim Mahrooz3, Mohammad Bagher Hashemi-Soteh4, Adele Bahar1, Ahad Alizadeh5.   

Abstract

AIMS: Insulin resistance is characterized by impaired biological response of peripheral tissues to the metabolic effects of insulin. Organic cation transporter 2 (OCT2) is responsible for 80% metformin clearance. Limited information is available on the potential relationship between genetic variants of OCT2 and insulin resistance. In this study, we examined the role of OCT2-T201M (602 C>T) variant in insulin resistance in patients with type 2 diabetes (T2D) who were treated with metformin.
METHODS: Serum concentrations of insulin and C-peptide were assessed using ELISA. Homeostasis model assessment for insulin resistance (HOMA-IR) and HOMA for beta cell function (HOMA-BCF) were determined. PCR-based restriction fragment length polymorphism was used to genotype the OCT2-T201M variant.
RESULTS: Patients with minor alleles had higher HbA1c concentrations (p=0.019), fasting glucose levels (p=0.023), HOMA-IR (p=0.03), and HOMA-BCF (p=0.26) than patients with common alleles. Multivariate analysis identified a significant association between the variables OCT2-T201M and gender, with HOMA-IR and HOMA-BCF (Wilks' λ=0.549, F=12.71, p<0.001 for OCT2-T201M and Wilks' λ=0.369, F=26.46, p<0.001 for gender. Changes in HOMA-BCF were inversely correlated with changes in fasting glucose levels (r=-0.412, p=0.008) and HbA1c (r=-0.257, p=0.114).
CONCLUSIONS: Our findings suggest that the loss-of-function variant OCT2-T201M (rs145450955) contribute to changes in insulin resistance and beta cell activity in patients with T2D treated with metformin. Moreover, gender as an independent variable has a significant relationship with HOMA-BCF.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  HOMA-BCF; HOMA-IR; Metformin; OCT2–T201M; Organic cation transporter; Type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 25662675     DOI: 10.1016/j.diabres.2015.01.024

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  11 in total

Review 1.  Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.

Authors:  M A Daniels; C Kan; D M Willmes; K Ismail; F Pistrosch; D Hopkins; G Mingrone; S R Bornstein; A L Birkenfeld
Journal:  Pharmacogenomics J       Date:  2016-07-19       Impact factor: 3.550

Review 2.  Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.

Authors:  Harald Staiger; Elke Schaeffeler; Matthias Schwab; Hans-Ulrich Häring
Journal:  Rev Diabet Stud       Date:  2016-02-10

3.  Allele frequency and genotype distribution of a common variant in the 3´-untranslated region of the SLC22A3 gene in patients with type 2 diabetes: Association with response to metformin.

Authors:  Maryam Ghaffari-Cherati; Abdolkarim Mahrooz; Mohammad Bagher Hashemi-Soteh; Seyyedeh Raheleh Hosseyni-Talei; Ahad Alizadeh; Saeid Mofid Nakhaei
Journal:  J Res Med Sci       Date:  2016-10-18       Impact factor: 1.852

4.  Association between the synonymous variant organic cation transporter 3 (OCT3)-1233G>A and the glycemic response following metformin therapy in patients with type 2 diabetes.

Authors:  Seyyedeh Raheleh Hosseyni-Talei; Abdolkarim Mahrooz; Mohammad Bagher Hashemi-Soteh; Maryam Ghaffari-Cherati; Ahad Alizadeh
Journal:  Iran J Basic Med Sci       Date:  2017-03       Impact factor: 2.699

Review 5.  Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine.

Authors:  Gaia Chiara Mannino; Francesco Andreozzi; Giorgio Sesti
Journal:  Diabetes Metab Res Rev       Date:  2019-01-07       Impact factor: 4.876

6.  Paraoxonase-2 variants potentially influence insulin resistance, beta-cell function, and their interrelationships with alanine aminotransferase in type 2 diabetes.

Authors:  Durdi Qujeq; Abdolkarim Mahrooz; Ahad Alizadeh; Ruzbeh Boorank
Journal:  J Res Med Sci       Date:  2018-12-28       Impact factor: 1.852

7.  SLC22A1 rs622342 Polymorphism Predicts Insulin Resistance Improvement in Patients with Type 2 Diabetes Mellitus Treated with Metformin: A Cross-Sectional Study.

Authors:  Kunrong Wu; Xiaoli Li; Yuedong Xu; Xiaoqian Zhang; Ziwan Guan; Shufang Zhang; Yan Li
Journal:  Int J Endocrinol       Date:  2020-05-08       Impact factor: 3.257

Review 8.  Genetics of Body Fat Distribution: Comparative Analyses in Populations with European, Asian and African Ancestries.

Authors:  Chang Sun; Peter Kovacs; Esther Guiu-Jurado
Journal:  Genes (Basel)       Date:  2021-05-29       Impact factor: 4.096

9.  The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.

Authors:  Zahra Kashi; Abdolkarim Mahrooz; Anvarsadat Kianmehr; Ahad Alizadeh
Journal:  PLoS One       Date:  2016-03-15       Impact factor: 3.240

Review 10.  The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.

Authors:  Zulfan Zazuli; Naut J C B Duin; Katja Jansen; Susanne J H Vijverberg; Anke H Maitland-van der Zee; Rosalinde Masereeuw
Journal:  Int J Mol Sci       Date:  2020-09-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.